Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic fibroblast injections for recessive dystrophic epidermolysis bullosa
ACTRN12610000760077Phase 2Completed
- Sponsor
- Research Infrastructure Support Services
- Start
- Oct 2008
- Modality
- Cell Therapies
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of allogeneic fibroblasts in Recessive Dystrophic Epidermolysis Bullosa (RDEB) (2 arms), sponsored by Research Infrastructure Support Services. Primary endpoints: Change in wound area from baseline at Week 48, Change in collagen VII expression and anchoring fibril ultrastructure at Week 48 and 1 more. Started Oct 2008; status: completed.
02
Drugs
allogeneic fibroblasts
03
Conditions
Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Beyond the preview
Go deeper on ACTRN12610000760077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000760077.